Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Business, Policy & Funding › Business News › Bolt Biotherapeutics Raises $93.5M in Series C Financing to Advance BDC-1001

Bolt Biotherapeutics Raises $93.5M in Series C Financing to Advance BDC-1001

Jul 01, 2020
|
staff reporter

NEW YORK – Bolt Biotherapeutics said on Wednesday that it closed a $93.5 million Series C financing round led by Sofinnova Investments.

New investors, including RA Capital Management, Surveyor Capital, Rock Springs Capital, Samsara BioCapital, and Pfizer Ventures, participated in the funding round alongside existing investors Novo Holdings, Vivo Capital, Pivotal bioVenture Partners, and others.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Featured Webinar

Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Featured Webinar

Precision Oncology in Melanoma Patients Treated with Immunotherapy: Clinical and Technological Perspective

Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

What's Popular?

In Cancer

  1. NCI Director Sharpless Outlines Ideas to Aggressively Lower Cancer Deaths

  2. Carisma Therapeutics Taps Into Innate Immune System to Extend CAR Therapy to Solid Tumors

    Premium

  3. Verastem Oncology's Combination Therapy Advances in KRAS-Mutated Lung Cancer

    Premium

  4. Oncocyte AACR Data Expands Potential Applications for Immunotherapy Response Predictor

  5. Immunocore's Tebentafusp Prolongs Survival in Uveal Melanoma Patients, AACR Study Shows

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.